The Company Chemists’ Association (CCA) today (26 October) calls on the UK Government to strengthen medicines contingency planning for Brexit, and consider planning beyond the six weeks currently advised to avoid shortages of medicines.
In its written evidence to the House of Commons Health and Social Care Committee on the impact of a no-deal Brexit, the CCA sets out its concern that shortages of certain medicines could arise and put patient care at risk, unless clear and robust plans for medicines supply are in place as soon as possible.
Malcolm Harrison, Chief Executive of the CCA, said: “CCA member companies are at the sharp end of patient care in communities across the UK and want to ensure they can continue to meet patient need and provide accurate information to patients and the public about how they can access their medicines”.
The CCA’s written evidence to the Health and Social Care Committee inquiry is available here.